BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xenome Ltd Grants MedImmune License to xdiscover(TM) Venom Peptide Library


1/8/2009 11:39:32 AM

Brisbane, Australia. 8 January 2009: Xenome Limited (“Xenome”) today announced it has executed a research licence agreement with MedImmune LLC (‘MedImmune”), a wholly owned subsidiary of AstraZeneca.

Under the partnership MedImmune will gain access to Xenome’s xdiscover™ venom peptide library to exclusively screen for drug candidates against two undisclosed targets involved in key pain pathways.

The financial terms of the agreement remain confidential, however Xenome will receive an up-front cash payment for access to the xdiscover™ library. In addition, the partnership allows for MedImmune to fund research at Xenome relating to SAR (structure activity relationship) studies on ‘hits’ from the Xenome library.

The licence agreement also provides MedImmune with the option to enter into product licences on selected peptides from the Xenome library, which will trigger undisclosed milestone and royalty payments.

“We are delighted to bring MedImmune on board as a discovery partner,” stated Xenome’s Chief Executive Officer, Dr Ian Nisbet. “Together with our partnership with Amylin, the relationship with MedImmune underscores the potential for Xenome’s discovery platform to deliver novel drug candidates. We are seeing significant interest in peptide drug discovery amongst both biotechnology and pharmaceutical companies and aim to execute further partnerships during 2009.”

The xdiscover™ library is a proprietary collection of more than 2000 primarily venom-derived peptides and is the result of a unique genomics capability that allows for the highly efficient discovery of novel peptides from cone snail venom tissue. Through the identification of venom peptide sequences, this genetic resource has been transformed into high quality synthesised peptides arrayed into a library suitable for high throughput screening.

About Xenome:

Xenome is a biotechnology company focused on the discovery and development of peptide-based therapeutics. The Company's lead product, Xen2174, is a novel conopeptide analogue for the treatment of moderate to severe pain. Xen2174 is a non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain. In an international phase I/II clinical trial in cancer patients, a single intrathecal administration of Xen2174 was found to be safe and well-tolerated across a broad dose range. In addition, the study provided evidence for an analgesic effect that had a rapid onset of action and was long-lasting.

Xenome's discovery platform is based on proprietary libraries of venom peptides, analogues and mimetics. In November 2007 Xenome and Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) entered into a partnership to screen Xenome's xdiscover™ library for new drug candidates against metabolic and musculoskeletal disease targets. Both Xen2174 and the Amylin partnership leverage off Xenome's unique expertise in peptide chemistry and its ability to translate the evolutionary advantages inherent in venom peptides into highly bioactive, drug-like molecules.

Further information can be obtained from the Xenome website (www.xenome.com).

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES